DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Surgery Plus Intraoperative Peritoneal Hyperthermic Chemotherapy (IPHC) to Treat Peritoneal Carcinomatosis

Information source: Wuhan University
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Stomach Neoplasms; Colorectal Neoplasms; Neoplasm Metastasis; Mesothelioma

Intervention: cytoreductive surgery (Procedure); intraoperative peritoneal hyperthermic chemotherapy with cisplatin and mitomycin (Procedure)

Phase: Phase 2

Status: Recruiting

Sponsored by: Wuhan University

Official(s) and/or principal investigator(s):
Yan Li, M.D., Ph.D, Principal Investigator, Affiliation: Cancer Center of Wuhan University
Yonemura Yutaka, MD, PhD, Principal Investigator, Affiliation: NPO Organization to Support Peritoneal Dissemination Treatment

Overall contact:
Yan Li, M.D., Ph.D, Phone: +86-27-62337478, Email: liyansd2@163.com

Summary

OBJECTIVES:

- Determine response and survival of patients with peritoneal carcinomatosis treated with

cytoreductive surgery plus intraoperative peritoneal hyperthermic chemotherapy with cisplatin and mitomycin

- Assess the quality of life of patients treated with this regimen.

OUTLINE: Patients are randomized into IPHC group and control group. In the former group, the patients undergo cytoreductive surgery plus intraoperative hyperthermic peritoneal perfusion with cisplatin and mitomycin over 60 minutes. Patients in the control group just underwent routine cytoreductive surgery. All patients in both groups receive the standard conventional chemotherapy after surgery. Quality of life is assessed at study initiation, at 1, 3, 6 months. Patients are followed at 4 weeks, every 3 months for 1 year, and then every 6 months for up to 3 years.

Clinical Details

Official title: Cytoreductive Surgery Plus Intraoperative Peritoneal Hyperthermic Chemotherapy for the Treatment of Peritoneal Carcinomatosis From Gastrointestinal Cancer: an Open Label, Randomized, Prospective, Phase 2 Clinical Trial

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: overall survival time

Secondary outcome: perioperative morbidity and mortality

Detailed description: DISEASE CHARACTERISTICS:

- Histologically confirmed peritoneal carcinomatosis with the following histologies:

- Primary peritoneal mesothelioma

- Adenocarcinoma of gastrointestinal tract origin

- Confined to peritoneal cavity

- Tumor mass could be debulked to less than 2. 5 cm in diameter per tumor deposit

- Must not have failed prior intraperitoneal platinum therapy

- Treatment failure is defined as radiographic evidence of disease progression on 2

consecutive CT scans within 3 months after therapy PATIENT CHARACTERISTICS: Age:

- 20 to 70 years old

Performance status:

- KPS>50

Life expectancy:

- More than 8 weeks

Hematopoietic:

- WBC at least 3,500/mm^3

- Platelet count at least 80,000/mm^3

Hepatic:

- Bilirubin no greater than 2 times upper limit of normal (ULN)

- AST and ALT no greater than 2 times ULN

- Liver enzymes no greater than 2 times ULN

Renal:

- Creatinine no greater than 1. 5 mg/dL

Cardiovascular:

- No significant irreversible cardiac ischemia

- No significant changes in ECG recording

Pulmonary:

- FEV_1 at least 1. 2 liters

- Maximum voluntary ventilation at least 50% expected

Other:

- Not pregnant or nursing

- Negative pregnancy test

- No concurrent medical problems that would preclude surgery

Eligibility

Minimum age: 20 Years. Maximum age: 70 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Gastric cancer or colorectal cancer with peritoneal carcinomatosis

- Gastric cancer or colorectal cancer with malignant ascites

- Karnofsky Performance Scale(KPS)>50

Exclusion Criteria:

- Age less than 20 years old, or beyond 70 years old

- Any lung metastasis, liver metastasis, or prominent retroperitoneal lymph node

metastasis

- Bilirubin greater than 3 times upper limit of normal (ULN)

- AST and ALT greater than 5 times ULN

- Liver enzymes greater than 3 times ULN

Locations and Contacts

Yan Li, M.D., Ph.D, Phone: +86-27-62337478, Email: liyansd2@163.com

Cancer Center of Wuhan University & Department of Oncology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071, China; Recruiting
Yan Li, M.D., Ph.D, Phone: +86-27-67813152, Ext: 3152, Email: liyansd2@163.com
Yonemura Yutaka, M.D., Ph.D, Phone: +81-072-433-2131, Email: y.yonemura@coda.ocn.ne.jp
Guo-Liang Yang, M.D, Sub-Investigator
Fu-Lin Cheng, M.D., Sub-Investigator
Yan Li, M.D., Ph.D, Principal Investigator
Mao-Hui Feng, M.D., Ph.D, Sub-Investigator
Shibo Masaya, M.D., Sub-Investigator
Additional Information

Related publications:

Yang XJ, Li Y, al-shammaa Hassan AH, Yang GL, Liu SY, Lu YL, Zhang JW, Yonemura Y. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival in selected patients with peritoneal carcinomatosis from abdominal and pelvic malignancies: results of 21 cases. Ann Surg Oncol. 2009 Feb;16(2):345-51. doi: 10.1245/s10434-008-0226-2. Epub 2008 Nov 19.

Starting date: March 2007
Last updated: February 12, 2009

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017